{"id":"deb-tace-plus-sorafenib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity / elevated liver enzymes"},{"rate":null,"effect":"Hand-foot skin reaction (sorafenib)"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea / vomiting"},{"rate":null,"effect":"Post-embolization syndrome (fever, pain)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DEB-TACE (drug-eluting bead transarterial chemoembolization) is a locoregional therapy that uses microspheres loaded with doxorubicin to deliver high drug concentrations directly to the tumor vasculature while occluding blood supply. Sorafenib is a multi-kinase inhibitor targeting VEGFR, PDGFR, RAF, and FLT3, which suppresses angiogenesis and tumor cell proliferation systemically. The combination aims to enhance efficacy through complementary mechanisms: local chemotherapy plus vascular disruption combined with systemic tyrosine kinase inhibition.","oneSentence":"DEB-TACE delivers doxorubicin directly to hepatocellular carcinoma via drug-eluting beads, while sorafenib systemically inhibits multiple tyrosine kinases to suppress tumor growth and angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:53.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), intermediate to advanced stage"}]},"trialDetails":[{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT02794337","phase":"PHASE2, PHASE3","title":"TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer","status":"UNKNOWN","sponsor":"Tata Memorial Hospital","startDate":"2014-12","conditions":"Carcinoma, Hepatocellular","enrollment":67},{"nctId":"NCT04127396","phase":"PHASE4","title":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-09-01","conditions":"Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus","enrollment":72},{"nctId":"NCT02460991","phase":"PHASE3","title":"A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Boston Scientific Corporation","startDate":"2015-11","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma","enrollment":2},{"nctId":"NCT04229355","phase":"PHASE3","title":"DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-02-02","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT04479527","phase":"PHASE2","title":"Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-04","conditions":"Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT04143191","phase":"PHASE3","title":"Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-09-15","conditions":"Hepatocellular Carcinoma","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DEB-TACE plus Sorafenib","genericName":"DEB-TACE plus Sorafenib","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DEB-TACE (Transarterial chemoembolization) combined with Sorafenib is used to treat patients with Hepatocellular Carcinoma (HCC) and Portal Vein Tumor Thrombus. Sorafenib is a small molecule serine/threonine-protein kinase RAF inhibitor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}